|
 The companies and the National Institutes of Health
(NIH) will share scientists, tissue and blood samples, and data, to
identify targets for new drugs for diseases such as Alzheimer's,
Type 2 diabetes, rheumatoid arthritis and lupus, the Journal said.
The collaboration, called the Accelerating Medicines Partnership,
will cost about $230 million and involves drugmakers such as
Bristol-Myers Squibb Co, Johnson & Johnson, GlaxoSmithKline, Takeda
Pharmaceuticals and Sanofi. (http://link.reuters.com/guw56v)
The agreement prohibits participants from using any discovery for
their own drug development until the project makes data public on
that discovery.
The NIH, GlaxoSmithKline, Bristol-Myers, Sanofi, Takeda, and Johnson
& Johnson could not be immediately reached for comments by Reuters.
(Reporting by Shubhankar Chakravorty
in Bangalore; Editing by Supriya Kurane)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
